A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Running, not enrolling · Phase 2/Phase 3

Conditions studied: Infantile Neuroaxonal Dystrophy

In brief

The purpose of this study is to evaluate the efficacy and safety of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD).

Key facts

Study ID

NCT03570931

Run by

Biojiva LLC

People needed

19

Starts

2018-11-05

Expected to finish

2022-06-30

Last updated by the study team

2021-10-14

Who can join

Age: 2 and older, up to 10. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female 18 months to 10 years of age
• Medical history consistent with the symptoms of classic INAD (onset of symptoms between the ages of 6 months and 3 years)
• Homozygous for PLA2G6 deficiency (variant alleles may be mixed heterozygotes)
• Must have impairment in at least 2 of the assessed categories at baseline
• Signed informed consent form (ICF) prior to entry into the study
• Able to provide the necessary blood samples

You may not qualify if…

• Received treatment with other experimental therapies within the last 30 days prior to the first dose
• Requiring mechanical ventilation, other than positive air pressure support primarily for mitigation of sleep apnea.
• Have a life expectancy of less than one year
• Diagnosis of atypical NAD (ANAD)
• Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to return for visits as scheduled

Where it is running

• University of California San Francisco, Benioff Children's Hospital — San Francisco, California, United States
• Jacobs Levy Genomics and Research Program — Morristown, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.